Alessandro Larcher

Dr. Alessandro Larcher

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in European Urology
Verified
Journal Article
Closed access
ABAlberto Briganti
Alberto Briganti
ALAlessandro Larcher
Alessandro Larcher
FAFiras Abdollah
Firas Abdollah
UCUmberto Capitanio
Umberto Capitanio
AGAndrea Gallina
Andrea Gallina
FMFrancesco Montorsi
Francesco Montorsi

1 February 2019 in European Urology
Verified
Journal Article
Closed access
ALAlessandro Larcher
Alessandro Larcher
FMFabio Muttin
Fabio Muttin
BPBenoit Peyronnet
Benoit Peyronnet
GNGeert De Naeyer
Geert De Naeyer
ZKZine-Eddine Khene
Zine-Eddine Khene
AMAlexandre Mottrie
Alexandre Mottrie

1 August 2018 in European Urology
Verified
Journal Article
Open access
Riccardo BertoloRiccardo Bertolo
Riccardo Bertolo
RARiccardo Autorino
Riccardo Autorino
GSGiuseppe Simone
Giuseppe Simone
IDIthaar Derweesh
Ithaar Derweesh
JGJuan D. Garisto
Juan D. Garisto
FPFrancesco Porpiglia
Francesco Porpiglia
While partial nephrectomy (PN) represents the standard surgical management for cT1 renal masses, its role for cT2 tumors is controversial. Robot-assisted PN (RAPN) is being increasingly implemented worldwide. To analyze perioperative, functional, and oncological outcomes of RAPN for cT2 tumors. Retrospective analysis of a large multicenter, multinational dataset of patients with nonmetastatic cT2 masses treated with robotic surgery (ROSULA: RObotic SUrgery for LArge renal mass). Robotic-assisted PN. Patients' demographics, lesion characteristics, perioperative variables, renal functional data, pathology, and oncological data were analyzed. Univariable and multivariable regression analyses assessed the relationships with the risk of intra-/postoperative complications, recurrence, and survival. A total of 298 patients were analyzed. Median tumor size was 7.6 (7-8.5) cm. Median RENAL score was 9 (8-10). Median ischemia time was 25 (20-32) min. Median estimated blood loss was 150 (100-300) ml. Sixteen patients had intraoperative complications (5.4%), whereas 66 (22%) had postoperative complications (5% were Clavien grade ≥3). Multivariable analysis revealed that a lower RENAL score (odds ratio [OR] 0.46, 95% confidence interval [CI] 0.21-0.65, p=0.02) and pathological pT2 stage (OR 0.51, 95% CI 0.12-0.86, p=0.001) were protective against postoperative complications. A total of 243 lesions (82%) were malignant. Twenty patients (8%) had positive surgical margins. Ten deaths and 25 recurrences/metastases occurred at a median follow-up of 12 (5-35) mo. At univariable analysis, higher pT stage was predictive of a likelihood of recurrences/metastases (p=0.048). While there was a significant deterioration of renal function at discharge, this remained stable over time at 1-yr follow-up. The main limitation of this study is its retrospective design. RAPN in the setting of select cT2 renal masses can safely be performed with acceptable outcomes. Further studies are warranted to corroborate our findings and to better define the role of robotic nephron sparing for this challenging indication. This report shows that robotic surgery can be used for safe removal of a large renal tumor in a minimally invasive fashion, maximizing preservation of renal function, and without compromising cancer control.

1 October 2012 in European Urology
Verified
Journal Article
Closed access
NBNicolòmaria Buffi
Nicolòmaria Buffi
GLGiuliana Lista
Giuliana Lista
ALAlessandro Larcher
Alessandro Larcher
GLGiovanni Lughezzani
Giovanni Lughezzani
VFVincenzo Ficarra
Vincenzo Ficarra
GGGiorgio Guazzoni
Giorgio Guazzoni

1 January 2015 in European Urology
Verified
Journal Article
Closed access
NFNicola Fossati
Nicola Fossati
QTQuoc-Dien Trinh
Quoc-Dien Trinh
JSJesse Sammon
Jesse Sammon
ASAkshay Sood
Akshay Sood
ALAlessandro Larcher
Alessandro Larcher
FAFiras Abdollah
Firas Abdollah

1 September 2014 in Journal of Urology
Verified
Journal Article
Closed access
GBGuido Barbagli
Guido Barbagli
SKSanjay B. Kulkarni
Sanjay B. Kulkarni
NFNicola Fossati
Nicola Fossati
ALAlessandro Larcher
Alessandro Larcher
SSSalvatore Sansalone
Salvatore Sansalone
Massimo LazzeriMassimo Lazzeri
Massimo Lazzeri
We investigated deterioration of the success rate of penile and bulbar substitution urethroplasty. We performed a retrospective descriptive analysis of patients who underwent substitution urethroplasty between July 1994 and September 2007. Inclusion criteria included 1-stage anterior urethroplasty using penile skin or oral mucosa with a minimum of 6 years followup. Patients with posterior urethral stricture, failed hypospadias or incomplete clinical records were excluded from analysis. The primary study outcome was postoperative failure-free survival and the secondary outcome was to identify significant predictors of treatment failure. The clinical outcome was considered a failure when any postoperative instrumentation was needed. Descriptive statistical analysis was done as well as Kaplan-Meier analysis, and univariable and multivariable Cox regression analysis. A total of 359 patients were included in study. Median followup was 118 months. Of the procedures 265 (73.8%) were successful and 94 (26.2%) failed, including 91 (96.8%) within the first 5 years. Substitute tissue type (oral mucosa vs skin) was the only significant predictor on univariable analysis (HR 1.86, p = 0.005). This result was confirmed by multivariable analysis adjusting for age at surgery, stricture length and etiology, urethroplasty type and previous treatments (HR 2.26, p = 0.001). Deterioration after anterior 1-stage substitution urethroplasty seems to develop within the first 5 years. Oral mucosa showed greater failure-free survival than penile skin and 1-stage penile urethroplasty showed the same success rate as bulbar urethroplasty.